News
Public · Published
Truist Securities maintains Chemours at Buy, lowers price target to $18 from $20
Truist Securities kept its Buy rating on Chemours but lowered its price target to $18 from $20, a 10% decrease. The new target is 37.5% above the stock's Nov. 3 closing price of $13.09. Recent analyst targets listed for Chemours range from $15 to $20.
Published:
Updated:
What happened
Truist Securities kept its Buy rating on Chemours but lowered its price target to $18 from $20, a 10% decrease. The new target is 37.5% above the stock’s Nov. 3 closing price of $13.09. Recent analyst targets listed for Chemours range from $15 to $20.
Confirmed
Global impact / market context
The lower target signals that Truist sees less potential value in Chemours than before, while its unchanged Buy rating still expresses a positive view. If investors use analyst targets to guide decisions, the revision could influence demand for the shares, though it does not change Chemours’ sales, costs, or cash directly.
Analyst inference
The four analyst notes listed from the past 30 days show targets between $15 and $20, with ratings ranging from Buy to Neutral and Equal-Weight. Truist’s new $18 target remains within that range, so this update is a change in one analyst’s view rather than a new consensus estimate.
Confirmed
What to watch
- Watch whether Truist makes another target or rating change; a further revision could alter how investors weigh its view against the other recent analyst notes. Analyst inference
- Compare any future Chemours analyst targets with the listed $15–$20 range; movement beyond it would show a view outside the recent set of estimates. Analyst inference
- Track whether Chemours’ reported business results support or challenge analysts’ views, since changes in revenue or costs could affect expectations for the company’s value. Analyst inference
Evidence
- Original source link unavailable